A phase 2 study of ibrutinib maintenance following first‐line high‐dose methotrexate‐based chemotherapy for elderly patients with primary central nervous system lymphoma

伊布替尼 医学 原发性中枢神经系统淋巴瘤 甲氨蝶呤 内科学 淋巴瘤 不利影响 化疗 临床研究阶段 肿瘤科 外科 白血病 慢性淋巴细胞白血病
作者
Osnat Bairey,Alisa Taliansky,Amir Glik,Alexandra Amiel,Shlomit Yust‐Katz,Ronit Gurion,Miri Zektser,David Henderson,Nadav Sarid,Netanel A. Horowitz,Takashi Shina,Eyal Lebel,Amos Cohen,Karyn Revital Geiger,Pia Raanani,Ofir Wolach,Tali Siegal
出处
期刊:Cancer [Wiley]
卷期号:129 (24): 3905-3914 被引量:3
标识
DOI:10.1002/cncr.34985
摘要

Abstract Background Elderly patients account for nearly 70% of all primary central nervous system lymphoma (PCNSL) cases. They cannot tolerate aggressive treatment and have poor prognosis with a median overall survival (OS) of less than 2 years and progression‐free survival (PFS) of 6–16 months. Ibrutinib penetrates the blood–brain barrier and has shown activity in PCNSL. Methods This prospective study investigated whether ibrutinib maintenance is feasible, and whether it can benefit elderly PCNSL patients in terms of expected 2‐year PFS. It is an open label, phase 2 study in newly diagnosed PCNSL patients 60–85 years old who responded to first‐line high‐dose methotrexate (HDMTX)‐based treatment with partial or complete response. Ibrutinib maintenance (560 mg/d) was continued until disease progression or intolerable toxicity. Results Twenty patients were enrolled, with a median age of 72 years (range, 61–80). Median time on ibrutinib maintenance was 12.5 (range, 2–46) months. Twelve patients stopped treatment: five due to central nervous system relapse and seven due to adverse events that were mainly grade 2. Five patients died (25%) all due to relapse. The 1‐ and 2‐year PFS are 90% and 72.6%, respectively, and the 2‐year OS is 89%. Conclusions The study reached its primary end points and also showed that ibrutinib maintenance is tolerated reasonably well by the elderly. Therefore, this study supports the concept that ibrutinib maintenance should be further evaluated as an optional consolidation measure in the elderly.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
MUAL完成签到,获得积分10
1秒前
企鹅公路完成签到,获得积分10
2秒前
埃特纳氏完成签到 ,获得积分10
3秒前
执笔完成签到,获得积分10
5秒前
heyan完成签到,获得积分10
5秒前
奥利奥完成签到,获得积分10
6秒前
满意代萱完成签到 ,获得积分10
6秒前
香蕉觅云应助零九三采纳,获得10
7秒前
orixero应助企鹅公路采纳,获得10
8秒前
时光路人完成签到,获得积分10
8秒前
LILYpig完成签到 ,获得积分10
8秒前
粗心的荷花完成签到 ,获得积分10
8秒前
9秒前
MOMO完成签到,获得积分10
11秒前
12秒前
殷勤柠檬完成签到,获得积分10
13秒前
13秒前
14秒前
上官若男应助52Hz采纳,获得10
14秒前
ZQP完成签到,获得积分10
15秒前
16秒前
殷勤柠檬发布了新的文献求助10
17秒前
17秒前
Q123ba叭完成签到 ,获得积分10
17秒前
ZQP发布了新的文献求助10
18秒前
zcbbb完成签到 ,获得积分10
18秒前
鲤鱼鑫磊发布了新的文献求助10
19秒前
雷霆康康完成签到,获得积分10
19秒前
夏天再见完成签到,获得积分10
20秒前
卡卡滴滴发布了新的文献求助10
20秒前
斯文败类应助后周寒生采纳,获得10
20秒前
11发布了新的文献求助10
21秒前
科目三应助鲤鱼鑫磊采纳,获得10
25秒前
高大凌寒应助稳重伊采纳,获得10
25秒前
零九三完成签到,获得积分10
25秒前
phg021发布了新的文献求助10
26秒前
高兴冬灵完成签到,获得积分20
26秒前
受伤的妙之应助ZQP采纳,获得10
27秒前
852应助ZQP采纳,获得10
27秒前
TG_FY完成签到,获得积分10
27秒前
高分求助中
Evolution 10000
ISSN 2159-8274 EISSN 2159-8290 1000
Becoming: An Introduction to Jung's Concept of Individuation 600
Ore genesis in the Zambian Copperbelt with particular reference to the northern sector of the Chambishi basin 500
A new species of Coccus (Homoptera: Coccoidea) from Malawi 500
A new species of Velataspis (Hemiptera Coccoidea Diaspididae) from tea in Assam 500
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3162623
求助须知:如何正确求助?哪些是违规求助? 2813541
关于积分的说明 7900768
捐赠科研通 2473078
什么是DOI,文献DOI怎么找? 1316652
科研通“疑难数据库(出版商)”最低求助积分说明 631468
版权声明 602175